
Despite President Bola Ahmed Tinubu’s executive order in June 2024 to reduce the cost of medicines, drug prices in Nigeria have continued to rise sharply, leaving patients and manufacturers without relief.
The order, signed on 28 June 2024, removed tariffs, excise duties, and Value Added Tax (VAT) on pharmaceutical machinery and raw materials. It was expected to reduce production costs, boost local drug manufacturing, and make medicines more affordable for ordinary Nigerians.
The Coordinating Minister of Health and Social Welfare, Professor Muhammad Pate, announced at the time that the executive order covered active pharmaceutical ingredients (APIs), excipients, syringes, needles, long-lasting insecticidal nets, and rapid diagnostic kits. He added that the policy required collaboration between the Ministries of Health, Finance, and Trade to ensure quick implementation and the removal of regulatory bottlenecks.
Pate explained that the policy would also introduce market-shaping mechanisms, such as framework contracts and volume guarantees, to encourage local manufacturers. Agencies including the Nigeria Customs Service (NCS), the National Agency for Food and Drug Administration and Control (NAFDAC), the Standards Organisation of Nigeria (SON), and the Federal Inland Revenue Service (FIRS), were directed to ensure smooth and speedy implementation.
On 26 March 2025, the Nigeria Customs Service announced that it had begun implementing the order. In a release signed by its National Public Relations Officer, Abdullahi Maiwada, the Service stated that critical raw materials used for drug production would now be exempted from import duty and VAT for two years. However, it noted that only pharmaceutical manufacturers recognised by the Federal Ministry of Health and in possession of valid Tax Identification Numbers would be eligible for the exemptions.
Despite these assurances, medicine prices have continued to rise. Data show that the prices of many essential drugs have increased by between 30 and 100 per cent in the past 14 months, adding to the financial burden of Nigerians already struggling with inflation and high living costs.
At the 2025 Annual Scientific Week of the Pharmaceutical Society of Nigeria (PSN) in Lagos, the Lagos State Chairman, Pharm. Babayemi Oyekunle, attributed the rise in drug prices to what he called “unfriendly government policies” and multiple fees imposed by NAFDAC.
According to him, NAFDAC charges Nigerian importers repeated inspection fees for the same foreign manufacturing sites. “The first importer from a foreign site pays $10,989.01, while other importers from the same site are charged $5,000 each for what the agency calls a ‘risk-based desk review’. This is unfair, harmful to businesses, and discourages competition, especially for small and medium-sized pharmaceutical companies,” Oyekunle said.
He also criticised NAFDAC for introduAPIcing new policies that could further raise drug costs, particularly the planned track-and-trace system that will require costly changes to packaging. “This new policy could increase the price of medicines by as much as 70 to 85 per cent,” he warned.
Oyekunle added that the agency was not aligning with the spirit of the executive order, which was aimed at making drugs cheaper. “Instead of implementing policies that would ease the burden on patients, NAFDAC appears more focused on revenue generation at the expense of the public,” he said.
Other stakeholders have also raised similar concerns. The CEO of Bloom Public Health, Professor Chimezie Anyakora, said the problem lies in both the slow pace of implementation and broader economic challenges.
“Firstly, the executive order is yet to be fully implemented,” Anyakora said. “The announcement is a step in the right direction but most manufacturers will only start reaping the effect in the future. It is also good to note that there are many other components that affect cost of production such as power, staff cost, cost of finance, and so on. Even if the policy were to be implemented today, it would still not bring a significant decrease in the cost of medical products.”
He stressed that the pharmaceutical industry does not operate in isolation. “The cost of production is shaped by the overall economic environment. Issues like erratic power supply, high-interest loans, and rising labour costs all add up. Unless these factors are addressed, the executive order alone cannot bring the expected relief.”
Former President of the Association of Industrial Pharmacists of Nigeria (NAIP), Pharm. Ignatius Anukwu, also expressed doubt about the policy’s immediate impact. He explained that the tax waivers only apply to raw materials for local manufacturing, which make up about 30 per cent of Nigeria’s drug supply. The other 70 per cent, which are imported finished medicines, remain unaffected.
“The first question to ask is, ‘What time frame did the policymakers have in mind to see the effects of this policy? One year? That is not probable,’” Anukwu said. “It may also be imagined that those who heard about the policy last year expected to see an impact much more quickly than the policy was designed to deliver.”
He outlined several reasons why drug prices have not dropped. “The policy of tax waiver is not significant compared to the inflationary rates within the period, not just of raw materials. Raw materials are only a component of what determines the price of the product. The medicines currently on the shelves were produced with inputs purchased in 2024 when the exchange rate of the naira to the dollar was at its weakest. Those medicines may have shelf lives of two to three years, so how can prices suddenly drop?” he asked.
He added that other dynamics such as interest rates, overheads, labour costs, and government charges have all risen, wiping out any potential benefits of the waivers. “We should also remember that the Nigeria Customs Service introduced a fee called ‘Port Fees’, which some reports suggest is more than 200 per cent higher than previous charges for certain products,” he noted.
Anukwu called for a more comprehensive policy. “A more strategic long-term approach should be adopted. Just a waiver of import duties may not do much. It could do something small but not much,” he said.
“A look at the ecosystem of drug production in the country will clearly show that long-term financing at low interest rates, patronage, and other protective policies to nurture and grow the industry is the way to go. So, the approach has to be comprehensive. Otherwise, we’ll continue to be import-dependent,” he added.
For now, Nigerians will continue to pay more for essential medicines despite government promises of cheaper drugs. Patients, pharmacists, and manufacturers are all calling on the Federal Government to move beyond policy announcements and implement practical measures that will make medicines affordable and accessible to all.





